202 related articles for article (PubMed ID: 30467600)
1. Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma.
Brunetti M; Holth A; Panagopoulos I; Staff AC; Micci F; Davidson B
Virchows Arch; 2019 Feb; 474(2):177-185. PubMed ID: 30467600
[TBL] [Abstract][Full Text] [Related]
2. Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.
Chowdhury S; Chen Y; Yao TW; Ajami K; Wang XM; Popov Y; Schuppan D; Bertolino P; McCaughan GW; Yu DM; Gorrell MD
World J Gastroenterol; 2013 May; 19(19):2883-93. PubMed ID: 23704821
[TBL] [Abstract][Full Text] [Related]
3. DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues.
Harstad EB; Rosenblum JS; Gorrell MD; Achanzar WE; Minimo L; Wu J; Rosini-Marthaler L; Gullo R; Ordway ND; Kirby MS; Chadwick KD; Cosma GN; Moyer CF
Regul Pept; 2013 Sep; 186():26-35. PubMed ID: 23850796
[TBL] [Abstract][Full Text] [Related]
4. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
[TBL] [Abstract][Full Text] [Related]
5. Advances in understanding the expression and function of dipeptidyl peptidase 8 and 9.
Zhang H; Chen Y; Keane FM; Gorrell MD
Mol Cancer Res; 2013 Dec; 11(12):1487-96. PubMed ID: 24038034
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase 9 (DPP9) in human skin cells.
Gabrilovac J; Čupić B; Zapletal E; Kraus O; Jakić-Razumović J
Immunobiology; 2017 Feb; 222(2):327-342. PubMed ID: 27682012
[TBL] [Abstract][Full Text] [Related]
7. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
[TBL] [Abstract][Full Text] [Related]
8. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
9. Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F
BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis.
Matheeussen V; Waumans Y; Martinet W; Van Goethem S; Van der Veken P; Scharpé S; Augustyns K; De Meyer GR; De Meester I
Basic Res Cardiol; 2013 May; 108(3):350. PubMed ID: 23608773
[TBL] [Abstract][Full Text] [Related]
11. Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
Stremenová J; Mares V; Lisá V; Hilser M; Krepela E; Vanicková Z; Syrucek M; Soula O; Sedo A
Int J Oncol; 2010 Feb; 36(2):351-8. PubMed ID: 20043068
[TBL] [Abstract][Full Text] [Related]
12. Profibrotic mechanisms of DPP8 and DPP9 highly expressed in the proximal renal tubule epithelial cells.
Zhang Y; Li K; Li Y; Zhao W; Wang L; Chen Z; Ma X; Yao T; Wang J; Dong W; Li X; Tian X; Fu R
Pharmacol Res; 2021 Jul; 169():105630. PubMed ID: 33932609
[TBL] [Abstract][Full Text] [Related]
13. The amino-dipeptidyl peptidases DPP8 and DPP9: Purification and enzymatic assays.
Donzelli L; Bolgi O; Geiss-Friedlander R
Methods Enzymol; 2023; 684():289-323. PubMed ID: 37230592
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors.
Huan Y; Jiang Q; Liu JL; Shen ZF
J Pharmacol Toxicol Methods; 2015; 71():8-12. PubMed ID: 25464020
[TBL] [Abstract][Full Text] [Related]
15. The SUMO1-E67 interacting loop peptide is an allosteric inhibitor of the dipeptidyl peptidases 8 and 9.
Pilla E; Kilisch M; Lenz C; Urlaub H; Geiss-Friedlander R
J Biol Chem; 2013 Nov; 288(45):32787-32796. PubMed ID: 24072711
[TBL] [Abstract][Full Text] [Related]
16. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
[TBL] [Abstract][Full Text] [Related]
17. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.
Onallah H; Catane LJ; Tropé CG; Hetland Falkenthal TE; Reich R; Davidson B
Virchows Arch; 2018 Oct; 473(4):463-470. PubMed ID: 30032361
[TBL] [Abstract][Full Text] [Related]
18. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
Broner EC; Tropé CG; Reich R; Davidson B
Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
[TBL] [Abstract][Full Text] [Related]
19. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases.
Qi SY; Riviere PJ; Trojnar J; Junien JL; Akinsanya KO
Biochem J; 2003 Jul; 373(Pt 1):179-89. PubMed ID: 12662155
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?
Van Goethem S; Matheeussen V; Joossens J; Lambeir AM; Chen X; De Meester I; Haemers A; Augustyns K; Van der Veken P
J Med Chem; 2011 Aug; 54(16):5737-46. PubMed ID: 21711053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
